RxDoctor Payments Data

James Kelly, MD

Ophthalmology · New York, NYNPI 1659361848

Payments from drug & device makers

$16,775in general payments, 2019–2025

Across 416 payments — averaging $40.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$8K
  • Carl Zeiss Meditec, Inc.$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • Harrow Eye, LLC$906
  • Johnson & Johnson Surgical Vision, Inc.$866
  • Bausch & Lomb Americas Inc.$709
  • plus $3K from 22 others

What the payments were for

  • Speaking & faculty fees$1,0506%
  • Travel & lodging$120%
  • Food & beverage$15,69394%
  • Gifts$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,775 in reported general payments places this provider in the 85th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$249,607
Medicare patients
360
Services billed
2,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine306$277,845
XiidraLifitegrast116$140,812
MieboPerfluorohexyloctane/Pf91$66,683
Restasis MultidoseCyclosporine80$50,815
CequaCyclosporine77$45,559
Cyclosporine44$19,286
CombiganBrimonidine Tartrate/Timolol42$9,664
Tobradex StTobramycin/Dexamethasone37$8,368
Prednisolone Acetate217$6,495
LumiganBimatoprost14$5,490
SimbrinzaBrinzolamide/Brimonidine Tart22$4,308
LotemaxLoteprednol Etabonate11$3,656
Brimonidine Tartrate40$3,511
Latanoprost321$2,570
Ketorolac Tromethamine119$1,916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Restasis Multidose, Combigan, Lumigan$511$343,813442 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$709$207,495207 claims
Sun Pharmaceutical Industries Inc.Cequa$1,276$45,55977 claims
Eyevance Pharmaceuticals LLCTobradex St$50$8,36837 claims
AlconSimbrinza$8,121$4,30822 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax$86$3,65611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →